Pharmaceuticals, Biotechnology and Life Sciences
Novartis has been cleared in Europe for Tafinlar combined with Mekinist (dabrafenib with trametinib) to treat patients with BRAF V600-with advanced non-small cell lung cancer (NSCLC).
Novo Nordisk said Monday that once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment.
InnovaDerma, a UK developer of life sciences, beauty and personal care products has secured new e-tailer distribution deals.
Avacta Group said on Monday that the first major immunogenicity study of Affimer technology using human ex-vivo samples was successful with a range of Affimer proteins shown to have low immunogenicity comparable with the marketed antibody Avastin.
Verona Pharma’s non-executive director Patrick Humphrey has decided to retire from the Board, effective April 15, 2017. The company said it doesn’t plan replacing him.
The drugstore chain Walgreens is taking a three-pronged approach to combat the public health crisis stemming from prescription opioids, according to a team of pharmacists and other clinicians from the company.
The Food and Drug Administration (FDA) has advised consumers not to purchase or use African Viagra, a product promoted for sexual enhancement.
U.S. Food and Drug Administration (FDA) has granted regular approval to AstraZeneca’s osimertinib (Tagrisso), for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.
DBV Technologies, the Geneva University Hospitals (HUG) and BioNet-Asia have announced results from a Phase I trial assessing Viaskin rPT`s ability to boost immunity against pertussis by epicutaneously administering two doses of BioNet`s recombinant pertussis toxin.